货号:A266562 同义名: (E/Z)-ON-01910 sodium;ON-01910 (sodium salt)
Rigosertib Sodium (Random Configuration) is a non-ATP-competitive inhibitor of PLK1 with IC50 of 9 nM in a cell-free assay. It shows 30-fold greater selectivity against Plk2 and no activity to Plk3.
规格 | 价格 | 会员价 | 库存 | 数量 | |||
---|---|---|---|---|---|---|---|
{[ item.pr_size ]} |
{[ getRatePrice(item.pr_rmb, 1,1) ]} {[ getRatePrice(item.pr_rmb_sale, 1,1) ]} {[ suihuo_tips(item.pr_am, item.pr_size) ]} |
{[ getRatePrice(item.pr_rmb, 1,1) ]} {[ getRatePrice(item.pr_rmb,item.pr_rate,1) ]} {[ suihuo_tips(item.pr_am, item.pr_size) ]} |
{[ getRatePrice(item.pr_rmb, 1,1) ]}{[ suihuo_tips(item.pr_am, item.pr_size) ]} | {[ getRatePrice(item.pr_rmb_sale, 1,1) ]} {[ getRatePrice(item.pr_rmb,item.pr_rate,item.mem_rate) ]} {[ getRatePrice(item.pr_rmb,1,item.mem_rate) ]} | 现货 | 咨询 | - + |
快速发货 顺丰冷链运输,1-2 天到达
品质保证
技术支持
免费溶解
产品名称 | PLK1 ↓ ↑ | PLK2 ↓ ↑ | PLK3 ↓ ↑ | PLK4 ↓ ↑ | 其他靶点 | 纯度 | |||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
HMN-214 | ✔ | 99%+ | |||||||||||||||||
SBE13 HCl |
++++
PLK1, IC50: 200 pM |
98% | |||||||||||||||||
Onvansertib |
+++
PLK1, IC50: 2 nM |
99%+ | |||||||||||||||||
Volasertib |
++++
PLK1, IC50: 0.87 nM |
97% | |||||||||||||||||
GSK461364 |
+++
PLK1, Ki: 2.2 nM |
99%+ | |||||||||||||||||
MLN0905 |
+++
PLK1, IC50: 2 nM |
99%+ | |||||||||||||||||
Ro3280 |
++
PLK1, IC50: 3 nM |
99% | |||||||||||||||||
(E/Z)-Rigosertib sodium |
+
PLK1, IC50: 9 nM |
+
PLK2, IC50: 260 nM |
Bcr-Abl | 99%+ | |||||||||||||||
BI 2536 |
++++
PLK1, IC50: 0.83 nM |
++
PLK2, IC50: 3.5 nM |
+
PLK3, IC50: 9.0 nM |
99%+ | |||||||||||||||
CFI-400945 |
++
PLK4, IC50: 2.8 nM |
Tie-2 | 98% | ||||||||||||||||
1. 鼠标悬停在“+”上可以显示相关IC50的具体数值。"+"越多,抑制作用越强。2. "✔"表示该化合物对相应的亚型有抑制作用,但抑制强度暂时没有相关数据。 |
靶点 |
|
描述 | Rigosertib is non-ATP-competitive inhibitor to PLK1 with IC50 of 9 nM. Rigosertib also exhibits inhibition against PLK2, PDGFR, Flt1, BCR-ABL, Fyn, Src, and CDK1, with IC50 of 18-260 nM. Rigosertib shows cell killing activity against 94 different tumor cell lines with IC50 of 50-250 nM, including BT27, MCF-7, DU145, PC3, U87, A549, H187, RF1, HCT15, SW480, and KB cells. While in normal cells, such as HFL, PrEC, HMEC, and HUVEC, Rigosertib has little or no effect unless its concentration is greater than 5-10 μM. In HeLa cells, Rigosertib (100-250 nM) induces spindle abnormalities and apoptosis. Rigosertib also inhibits several multidrug resistant tumor cell lines, including MES-SA, MES-SA/DX5a, CEM, and CEM/C2a, with IC50 of 50-100 nM. In DU145 cells, Rigosertib (0.25-5 μM) blocks cell cycle progression in G2/M phase, results in an accumulation of cells containing subG1 content of DNA, and activates apoptotic pathways. In A549 cells, Rigosertib (50 nM-0.5 μM) induces loss of viability and caspase 3/7 activation. In a recent study, Rigosertib induces apoptosis in chronic lymphocytic leukemia (CLL) cells without toxicity against T-cells or normal B-cells. Rigosertib also abrogates the pro-survival effect of follicular dendritic cells on CLL cells and reduces SDF-1-induced migration of leukemic cells. |
细胞系 | 浓度 | 检测类型 | 检测时间 | 活动说明 | 数据源 |
human A2780 cells | Proliferation assay | 72 h | Antiproliferative activity against human A2780 cells assessed as cell growth inhibition after 72 hrs by MTT assay, GI50=62 nM | 24471873 | |
human A2780 cells | 0.25 μM | Function assay | 24 h | Reduction in Mcl1 level in human A2780 cells at 0.25 uM after 24 hrs by Western blot analysis | 24471873 |
human DU145 cells | Proliferation assay | 72 h | Antiproliferative activity against AR negative human DU145 cells assessed as cell growth inhibition after 72 hrs by MTT assay, GI50=75 nM | 24471873 | |
human DU145 cells | Cytotoxic assay | 96 h | Cytotoxicity against human DU145 cells after 96 hrs by trypan blue exclusion assay, IC50=75 nM | 21812421 | |
计算器 | ||||
存储液制备 | 1mg | 5mg | 10mg | |
1 mM 5 mM 10 mM |
2.11mL 0.42mL 0.21mL |
10.56mL 2.11mL 1.06mL |
21.12mL 4.22mL 2.11mL |
CAS号 | 1225497-78-8 |
分子式 | C21H24NNaO8S |
分子量 | 473.472 |
别名 | (E/Z)-ON-01910 sodium;ON-01910 (sodium salt);ON-01910;Rigosertib |
运输 | 蓝冰 |
存储条件 |
液体 -20°C:3-6个月-80°C:12个月 粉末 Keep in dark place,Inert atmosphere,2-8°C |
溶解度 | |
动物实验配方 |
PO 0.5% CMC-Na 40 mg/mL suspension |